
Lantern Pharma Q3 Results: $4M Financing, Clinical Updates, CEO Transition
Lantern Pharma Inc. announced its third quarter 2026 financial results and provided several business updates. Key developments include the engagement of the first clinical site for a Phase 1b/2 trial in triple-negative breast cancer, the opening of Part 2 of the HARMONIC™ trial in Taiwan and the U.S. for LP-300, and the peer-reviewed publication of LP-184 Phase 1a glioblastoma data. The company also closed a $4.0 million registered direct offering and announced a leadership transition with the appointment of David Margrave as Interim CEO. Additionally, Lantern reached an agreement in principle to settle claims with a former consultant for $2.0 million and formed a new subsidiary, Open Medicine AI, to commercialize its AI platform.
Key Highlights
- Lantern Pharma closed a $4.0 million registered direct offering and concurrent private placement on September 30, 2026.
- First clinical site engaged for Phase 1b/2 trial of LP-184 in triple-negative breast cancer.
- Taiwan FDA approved amended HARMONIC™ protocol for Phase 2 trial of LP-300; U.S. central IRB also approved.
- Peer-reviewed publication of LP-184 Phase 1a glioblastoma data supports planned Phase 1b/2a combination trial.
- Company reached agreement in principle to settle claims with a former consultant for $2.0 million.
- R&D expenses decreased 36% year over year to $1.6 million for Q3 2026.
- David Margrave appointed Interim Chief Executive Officer following Panna Sharma's resignation.
- Formed Open Medicine AI Inc. (OMAI) as a wholly-owned subsidiary to commercialize its AI platform.
Price Impact
More from LTRN